Effects of Nigella sativa oil supplementation on selected metabolic parameters and anthropometric indices in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial.
- 2021-04-13
- Phytotherapy research : PTR 35(7)
- Omid Mohammad Tavakoli-Rouzbehani
- Mohsen Abbasnezhad
- Sorayya Kheirouri
- Mohammad Alizadeh
- PubMed: 33851461
- DOI: 10.1002/ptr.7115
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 60
- Population
- 60 patients with coronary artery disease (CAD)
- Methods
- randomized, double-blind, placebo-controlled clinical trial, 2 g of Nigella sativa oil or sunflower oil as placebo for 8 weeks
- Blinding
- Double-blind
- Duration
- 8 weeks
- Funding
- Unclear
Various metabolic parameters are risk factors related to the amplified risk of atherosclerotic cardiovascular disease. A wide variety of data exist on Nigella sativa (NS) and metabolic parameters. The current study is designed to examine NS supplementation on lipid profile, blood pressure, glycemic control, anthropometric indices, and insulin resistance in individuals with coronary artery disease (CAD). In a randomized, double-blind, placebo-controlled clinical trial, 60 patients with CAD received either 2 g of NS oil or sunflower oil as a placebo for 8 weeks. Biochemical and anthropometric measurements were assessed. NS significantly reduced weight (-1.82 Kg; 95% C, [2.72, 4.13]), body mass index (-0.67 kg/m2 ; 95% C, [0.33, 1.01]), waist circumference (-2.15 cm; 95% C, [1.06, 3.23]), hip circumference (-1.26 cm; 95% C, [0.61, 1.910]), waist-to-hip ratio (0.008; 95%C, [0.001, 0.01]), systolic (-9.52 mmHg; 95% C, [7.14, 11.9]), diastolic blood pressure (-8.26 mmHg; 95% C, [4.89, 11.62]), and fasting blood glucose (FBS) (-4.32 mg/dl; 95% C, [-0.51, 9.15]) as compared with the placebo group. The results indicate a potential beneficiary effect of NS on the metabolic parameters in CAD patients including improvements in anthropometric indices, blood pressure, and FBS.
Research Insights
body mass index (-0.67 kg/m2 ; 95% C, [0.33, 1.01])
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 2 g/day
NS significantly reduced weight (-1.82 Kg; 95% C, [2.72, 4.13])
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 2 g/day
diastolic blood pressure (-8.26 mmHg; 95% C, [4.89, 11.62])
- Effect
- Beneficial
- Effect size
- Large
- Dose
- 2 g/day
fasting blood glucose (FBS) (-4.32 mg/dl; 95% C, [-0.51, 9.15])
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 2 g/day
hip circumference (-1.26 cm; 95% C, [0.61, 1.910])
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 2 g/day
systolic (-9.52 mmHg; 95% C, [7.14, 11.9])
- Effect
- Beneficial
- Effect size
- Large
- Dose
- 2 g/day
waist circumference (-2.15 cm; 95% C, [1.06, 3.23])
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 2 g/day
waist-to-hip ratio (0.008; 95%C, [0.001, 0.01])
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 2 g/day